Unknown PHASE3 INTERVENTIONAL 2-arm NCT05305183

A Phase III Clinical Study of Minodronate Tablets in Postmenopausal Women With Osteoporosis

A Randomized, Double-blinded, Active-controlled, Multicentered Phase III Trial to Assess the Efficacy and Safety of Minodronate Tablets in Postmenopausal Women With Osteoporosis

Sponsor: Shandong New Time Pharmaceutical Co., LTD

Conditions Osteoporosis

Interventions Minodronate Tablets and Alendronate Sodium Tablets-matching placebo;Alendronate Sodium Tablets and Minodronate Tablets -matching placebo

Updated 3 times since 2022 Last updated: Mar 22, 2022 Started: May 31, 2022 Primary completion: May 31, 2023 Completion: May 31, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Osteoporosis, this trial is ongoing. The trial is conducted by Shandong New Time Pharmaceutical Co., LTD and has accumulated 3 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Not Yet Recruiting → Unknown
Apr 2022 — Jul 2024 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shandong New Time Pharmaceutical Co., LTD

Data source: Shandong New Time Pharmaceutical Co., LTD

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shandong, China